493 related articles for article (PubMed ID: 26366236)
21. Limitations of basing screening policies on screening trials: The US Preventive Services Task Force and Prostate Cancer Screening.
Etzioni R; Gulati R; Cooperberg MR; Penson DM; Weiss NS; Thompson IM
Med Care; 2013 Apr; 51(4):295-300. PubMed ID: 23269114
[TBL] [Abstract][Full Text] [Related]
22. Problems with prostate-specific antigen screening: a critical review.
Schmid HP; Prikler L; Semjonow A
Recent Results Cancer Res; 2003; 163():226-31; discussion 264-6. PubMed ID: 12903857
[TBL] [Abstract][Full Text] [Related]
23. Cancer surveillance series: interpreting trends in prostate cancer--part III: Quantifying the link between population prostate-specific antigen testing and recent declines in prostate cancer mortality.
Etzioni R; Legler JM; Feuer EJ; Merrill RM; Cronin KA; Hankey BF
J Natl Cancer Inst; 1999 Jun; 91(12):1033-9. PubMed ID: 10379966
[TBL] [Abstract][Full Text] [Related]
24. Standardisation of information submitted to an endpoint committee for cause of death assignment in a cancer screening trial – lessons learnt from CAP (Cluster randomised triAl of PSA testing for Prostate cancer).
Williams NJ; Hill EM; Ng SY; Martin RM; Metcalfe C; Donovan JL; Evans S; Hughes LJ; Davies CF; Hamdy FC; Neal DE; Turner EL;
BMC Med Res Methodol; 2015 Jan; 15():6. PubMed ID: 25613468
[TBL] [Abstract][Full Text] [Related]
25. Prostate cancer specific survival in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial.
Pinsky PF; Black A; Parnes HL; Grubb R; David Crawford E; Miller A; Reding D; Andriole G
Cancer Epidemiol; 2012 Dec; 36(6):e401-6. PubMed ID: 23000116
[TBL] [Abstract][Full Text] [Related]
26. Prostate specific antigen (PSA) testing as screening for prostate cancer: the current controversy.
Boyle P
Ann Oncol; 1998 Dec; 9(12):1263-4. PubMed ID: 9932152
[No Abstract] [Full Text] [Related]
27. Prostate cancer mortality after introduction of prostate-specific antigen mass screening in the Federal State of Tyrol, Austria.
Bartsch G; Horninger W; Klocker H; Reissigl A; Oberaigner W; Schönitzer D; Severi G; Robertson C; Boyle P;
Urology; 2001 Sep; 58(3):417-24. PubMed ID: 11549491
[TBL] [Abstract][Full Text] [Related]
28. Prostate-cancer mortality at 11 years of follow-up.
Schröder FH; Hugosson J; Roobol MJ; Tammela TL; Ciatto S; Nelen V; Kwiatkowski M; Lujan M; Lilja H; Zappa M; Denis LJ; Recker F; Páez A; Määttänen L; Bangma CH; Aus G; Carlsson S; Villers A; Rebillard X; van der Kwast T; Kujala PM; Blijenberg BG; Stenman UH; Huber A; Taari K; Hakama M; Moss SM; de Koning HJ; Auvinen A;
N Engl J Med; 2012 Mar; 366(11):981-90. PubMed ID: 22417251
[TBL] [Abstract][Full Text] [Related]
29. Lifetime and recent prostate specific antigen (PSA) screening of men for prostate cancer in Canada.
Beaulac JA; Fry RN; Onysko J
Can J Public Health; 2006; 97(3):171-6. PubMed ID: 16827400
[TBL] [Abstract][Full Text] [Related]
30. Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986-2005.
Welch HG; Albertsen PC
J Natl Cancer Inst; 2009 Oct; 101(19):1325-9. PubMed ID: 19720969
[TBL] [Abstract][Full Text] [Related]
31. Design and preliminary recruitment results of the Cluster randomised triAl of PSA testing for Prostate cancer (CAP).
Turner EL; Metcalfe C; Donovan JL; Noble S; Sterne JA; Lane JA; Avery KN; Down L; Walsh E; Davis M; Ben-Shlomo Y; Oliver SE; Evans S; Brindle P; Williams NJ; Hughes LJ; Hill EM; Davies C; Ng SY; Neal DE; Hamdy FC; Martin RM;
Br J Cancer; 2014 Jun; 110(12):2829-36. PubMed ID: 24867688
[TBL] [Abstract][Full Text] [Related]
32. Mortality results from a randomized prostate-cancer screening trial.
Andriole GL; Crawford ED; Grubb RL; Buys SS; Chia D; Church TR; Fouad MN; Gelmann EP; Kvale PA; Reding DJ; Weissfeld JL; Yokochi LA; O'Brien B; Clapp JD; Rathmell JM; Riley TL; Hayes RB; Kramer BS; Izmirlian G; Miller AB; Pinsky PF; Prorok PC; Gohagan JK; Berg CD;
N Engl J Med; 2009 Mar; 360(13):1310-9. PubMed ID: 19297565
[TBL] [Abstract][Full Text] [Related]
33. Practice of opportunistic prostate-specific antigen screening in Italy: data from the Health Search database.
D'Ambrosio G; Samani F; Cancian M; De Mola C
Eur J Cancer Prev; 2004 Oct; 13(5):383-6. PubMed ID: 15452450
[TBL] [Abstract][Full Text] [Related]
34. The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial of the National Cancer Institute: history, organization, and status.
Gohagan JK; Prorok PC; Hayes RB; Kramer BS;
Control Clin Trials; 2000 Dec; 21(6 Suppl):251S-272S. PubMed ID: 11189683
[TBL] [Abstract][Full Text] [Related]
35. PSA use and incidence of prostate biopsy in the Tuscany region: is opportunistic screening discounting biopsy in subjects with PSA elevation?
Ciatto S; Houssami N; Martinelli F; Giusti F; Zappa M
Tumori; 2008; 94(4):518-22. PubMed ID: 18822688
[TBL] [Abstract][Full Text] [Related]
36. Public knowledge of benefits of breast and prostate cancer screening in Europe.
Gigerenzer G; Mata J; Frank R
J Natl Cancer Inst; 2009 Sep; 101(17):1216-20. PubMed ID: 19671770
[TBL] [Abstract][Full Text] [Related]
37. PSA screening for prostate cancer: the current controversy--a viewpoint. Patient Outcomes Research Team for Prostatic Diseases.
Barry MJ
Ann Oncol; 1998 Dec; 9(12):1279-82. PubMed ID: 9932155
[TBL] [Abstract][Full Text] [Related]
38. The accuracy and effectiveness of routine population screening with mammography, prostate-specific antigen, and prenatal ultrasound: a review of published scientific evidence.
Woolf SH
Int J Technol Assess Health Care; 2001; 17(3):275-304. PubMed ID: 11495374
[TBL] [Abstract][Full Text] [Related]
39. National trends in the epidemiology of prostate cancer, 1973 to 1994: evidence for the effectiveness of prostate-specific antigen screening.
Farkas A; Schneider D; Perrotti M; Cummings KB; Ward WS
Urology; 1998 Sep; 52(3):444-8; discussion 448-9. PubMed ID: 9730458
[TBL] [Abstract][Full Text] [Related]
40. Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context.
Draisma G; Etzioni R; Tsodikov A; Mariotto A; Wever E; Gulati R; Feuer E; de Koning H
J Natl Cancer Inst; 2009 Mar; 101(6):374-83. PubMed ID: 19276453
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
